Advancing Lentiviral Vector Manufacturing at ASH 2025

December 6, 2025

uBriGene to Present High-Yield cGMP Lentiviral Vector Manufacturing Process at the 67th ASH Annual Meeting 2025

uBriGene Biosciences Inc., a global CDMO specializing in cell and gene therapy manufacturing, is pleased to announce its participation in the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6–9, 2025, in Orlando, Florida.

At the event, uBriGene will present a poster titled:
“Development of a High-Yield cGMP Lentiviral Vector Manufacturing Process Using Suspension Culture, a Syenex LVV Enhancer, and a Closed Aseptic System.”

Poster Details

Poster Details Session: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I Date: December 6, 2025 Time: 5:30 PM – 7:30 PM Room: OCCC – West Halls B3–B4

Session: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I
Date: December 6, 2025
Time: 5:30 PM – 7:30 PM
Venue: OCCC – West Halls B3–B4

The poster highlights uBriGene’s latest breakthrough in lentiviral vector (LVV) production, demonstrating how an optimized suspension-based system, combined with a Syenex LVV enhancer and closed aseptic technology, delivers high-yield, scalable, and regulatory-compliant manufacturing outcomes. This innovative process is designed to accelerate development timelines, enhance product consistency, and reduce production costs, helping therapy developers bring life-changing treatments to patients faster and more efficiently.

The ASH Annual Meeting serves as a global platform where leaders in hematology and cell therapy share the latest advancements in science, technology, and clinical application. uBriGene’s participation reinforces its non-stop effort to push the boundaries of viral vector manufacturing technology and to provide developers with robust, end-to-end manufacturing solutions that meet the highest cGMP standards.

Connect with Us at ASH 2025

To explore our poster presentation or schedule a partnering meeting during ASH 2025, please contact us. Let’s collaborate to bring transformative therapies to patients worldwide.